fluocortin-butyl-ester and Dermatitis

We report on 161 patients suffering from inflammatory dermatoses on hands, forearms, and lower legs who had been initially treated with 0.1% difluocortolone valerate. During the maintenance therapy carried out over a period of 3 to 4 weeks, we tested the efficacy of Kamillosan cream vs. 0.25% hydrocortisone, 0.75% fluocortin butyl ester, and 5% bufexamac in a bilateral comparative study. For the indications tested Kamillosan cream showed more or less equieffective therapeutic results as compared to 0.25% hydrocortisone. It is superior, however, to the non-steroidal anti-inflammatory agent 5% bufexamac as well as to 0.75% fluocortin butyl ester, a further glucocorticoid. With regard to neurodermitis, Kamillosan cream not only shows the same therapeutic effect as 0.25% hydrocortisone but is even of marked superiority towards other reference products.

Topics: Adolescent; Adult; Aged; Bufexamac; Chamomile; Clinical Trials as Topic; Dermatitis; Dermatitis, Contact; Dermatitis, Seborrheic; Diflucortolone; Female; Fluocortolone; Humans; Hydrocortisone; Hydroxamic Acids; Male; Middle Aged; Neurodermatitis; Oils, Volatile; Ointments; Plant Extracts; Plants, Medicinal

Topics: Adolescent; Adult; Aged; Bufexamac; Child; Child, Preschool; Clinical Trials as Topic; Dermatitis; Double-Blind Method; Fluocortolone; Humans; Hydroxamic Acids; Middle Aged; Random Allocation

Topics: Administration, Topical; Child; Child, Preschool; Dermatitis; Drug Combinations; Female; Fluocortolone; Humans; Infant; Male; Miconazole